肝细胞癌的遗传学分类。
Hepatocellular Carcinoma Genetic Classification.
机构信息
From the Division of Gastroenterology and Hepatology, University of Maryland School of Medicine.
Department of Medicine, University of Maryland Midtown Medical Center.
出版信息
Cancer J. 2023;29(5):249-258. doi: 10.1097/PPO.0000000000000682.
Abstract
Hepatocellular carcinoma (HCC) represents a significant global burden, with management complicated by its heterogeneity, varying presentation, and relative resistance to therapy. Recent advances in the understanding of the genetic, molecular, and immunological underpinnings of HCC have allowed a detailed classification of these tumors, with resultant implications for diagnosis, prognostication, and selection of appropriate treatments. Through the correlation of genomic features with histopathology and clinical outcomes, we are moving toward a comprehensive and unifying framework to guide our diagnostic and therapeutic approach to HCC.
摘要
肝细胞癌 (HCC) 是一种全球性的重大负担，其管理因肿瘤的异质性、不同表现和相对耐药性而变得复杂。近年来，人们对 HCC 的遗传、分子和免疫学基础有了更深入的了解，这使得对这些肿瘤进行详细分类成为可能，从而对诊断、预后和选择合适的治疗方法产生了影响。通过将基因组特征与组织病理学和临床结果相关联，我们正在朝着一个全面统一的框架发展，以指导我们对 HCC 的诊断和治疗方法。
相似文献
1
Hepatocellular Carcinoma Genetic Classification.肝细胞癌的遗传学分类。
Cancer J. 2023;29(5):249-258. doi: 10.1097/PPO.0000000000000682.
2
Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.基因组医学及其对肝细胞癌预防和治疗的影响。
Gastroenterology. 2019 Jan;156(2):492-509. doi: 10.1053/j.gastro.2018.11.001. Epub 2018 Nov 4.
3
Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies.肝细胞癌（HCC）的分子诊断和治疗：先进技术的新兴领域。
J Hepatol. 2012 Jan;56(1):267-75. doi: 10.1016/j.jhep.2011.07.007. Epub 2011 Jul 23.
4
Integration of genomic information in the clinical management of HCC.基因组信息在肝癌临床管理中的整合。
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):831-42. doi: 10.1016/j.bpg.2014.08.004. Epub 2014 Aug 23.
5
Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.成人肝细胞肿瘤细胞遗传学和分子生物学的最新进展：对影像学和治疗的影响。
Radiology. 2011 Mar;258(3):673-93. doi: 10.1148/radiol.10100376.
6
Fighting the bushfire in HCC trials.在肝癌试验中对抗丛林大火。 （不过此译文似乎逻辑不太清晰，可能原文有误，正常应该是“Fighting the battle in HCC trials”之类表述才更合理，直译为这样不太能准确理解其确切含义）
J Hepatol. 2011 Aug;55(2):276-7. doi: 10.1016/j.jhep.2011.03.004. Epub 2011 Mar 22.
7
Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas.原发性肝癌的罕见变异型：纤维板层样、混合型和肉瘤样肝细胞癌。
Eur J Med Genet. 2021 Nov;64(11):104313. doi: 10.1016/j.ejmg.2021.104313. Epub 2021 Aug 18.
8
Long non-coding RNAs in hepatocellular carcinoma: Ordering of the complicated lncRNA regulatory network and novel strategies for HCC clinical diagnosis and treatment.长链非编码 RNA 在肝细胞癌中的作用：复杂 lncRNA 调控网络的解析及用于 HCC 临床诊断和治疗的新策略。
Pharmacol Res. 2020 Aug;158:104848. doi: 10.1016/j.phrs.2020.104848. Epub 2020 May 7.
9
The advanced development of molecular targeted therapy for hepatocellular carcinoma.肝细胞癌的分子靶向治疗的进展。
Cancer Biol Med. 2022 Jun 15;19(6):802-17. doi: 10.20892/j.issn.2095-3941.2021.0661.
10
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment.微小RNA在肝细胞癌中的作用：从分子生物学到治疗
Molecules. 2014 May 19;19(5):6393-406. doi: 10.3390/molecules19056393.
引用本文的文献
1
Clinical Significance of Acyl-CoA Dehydrogenase Short Chain and Its Anti-tumor Role in Hepatocellular Carcinoma by Inhibiting Canonical Wnt/β-Catenin Pathway.酰基辅酶A脱氢酶短链的临床意义及其通过抑制经典Wnt/β-连环蛋白通路在肝细胞癌中的抗肿瘤作用
Dig Dis Sci. 2025 Feb;70(2):622-637. doi: 10.1007/s10620-024-08813-y. Epub 2025 Jan 2.
本文引用的文献
1
Hepatocellular carcinoma surveillance: current practice and future directions.肝细胞癌监测：当前实践与未来方向
Hepatoma Res. 2022;8. doi: 10.20517/2394-5079.2021.131. Epub 2022 Mar 11.
2
Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer.在肝细胞癌高危患者中使用定量免疫组织化学。
Genes Cancer. 2022 Jun 6;13:9-20. doi: 10.18632/genesandcancer.220. eCollection 2022.
3
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.肝细胞癌的分子发病机制和系统治疗。
Nat Cancer. 2022 Apr;3(4):386-401. doi: 10.1038/s43018-022-00357-2. Epub 2022 Apr 28.
4
Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion.NAFLD 相关肝癌的独特分子特征强调β-catenin/TNFRSF19 介导的免疫逃逸。
J Hepatol. 2022 Aug;77(2):410-423. doi: 10.1016/j.jhep.2022.03.015. Epub 2022 Mar 26.
5
Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma.液体活检在肝细胞癌中的临床应用
Front Oncol. 2022 Feb 8;12:781820. doi: 10.3389/fonc.2022.781820. eCollection 2022.
6
Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients.潜在的血浆生物标志物：miRNA-29c、miRNA-21 和 miRNA-155 在肝癌患者的临床进展中的作用。
PLoS One. 2022 Feb 14;17(2):e0263298. doi: 10.1371/journal.pone.0263298. eCollection 2022.
7
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.甲胎蛋白、甲胎蛋白异质体 3、脱γ-羧基凝血酶原在肝癌检测中的表现：美国的一项 3 期生物标志物研究。
Clin Gastroenterol Hepatol. 2023 Feb;21(2):415-423.e4. doi: 10.1016/j.cgh.2022.01.047. Epub 2022 Feb 3.
8
β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development.β2- spectrin（SPTBN1）作为饮食诱导性肝病和预防癌症发展的治疗靶点。
Sci Transl Med. 2021 Dec 15;13(624):eabk2267. doi: 10.1126/scitranslmed.abk2267.
9
Value of alpha-fetoprotein in hepatocellular carcinoma.甲胎蛋白在肝细胞癌中的价值。
Transl Gastroenterol Hepatol. 2021 Oct 25;6:52. doi: 10.21037/tgh.2019.12.19. eCollection 2021.
10
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
Zotero 插件